Metabolic Effects of Exogenous Glucocorticoids in Fasted Man

O. E. OWEN and G. F. CAHILL, JR.

From the Department of Medicine, Harvard Medical School, the Peter Bent Brigham Hospital, and the Joslin Diabetes Foundation, Inc., Boston, Massachusetts, 02215, and the Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19104

ABSTRACT The influence of administering excessive amounts of glucocorticoids on circulating substrates and hormones and on urinary excretion of nitrogenous compounds and ketone bodies was examined in man after prolonged starvation.

After 35 days of total caloric deprivation the administration of high physiologic doses of glucocorticoids increased circulating glucose and insulin levels without intensifying total urinary nitrogen excretion. The increased blood glucose seemed to be due to diminished peripheral uptake rather than augmented gluconeogenesis. A small, transient increase in circulating plasma amino acids was observed. However, the secondary rise in serum insulin seemed to block the proteolytic effect(s) of glucocorticoids, preventing them from mobilizing body protein stores during starvation. There was no change in circulating free fatty acids or glycerol. Thus, it appeared that the potential catabolic action of excessive glucocorticoids was offset by the anabolic effect of insulin, and a new state of homeostasis was established.

An additional effect of glucocorticoid administration was a marked diminution of renal excretion of ketone bodies.

INTRODUCTION

A metabolic steady state develops in humans after prolonged starvation and the body processes are comparable on a day-to-day basis (1, 2). Previous studies have shown that this steady state provides an ideal condition for investigating the acute metabolic effects of exogenously administered hormones (3–5). We took advantage of this steady state to investigate changes induced by glucocorticoid administration on circulating substrates and hormones as well as on the urinary excretion of nitrogenous compounds and ketone bodies.

METHODS

Subjects. Six obese volunteers were admitted to the Clinical Research Center of the Peter Bent Brigham Hospital to study the metabolic effects of glucocorticoid administration (Table 1). Each subject was informed of the potential risks involved in both starvation and exogenous glucocorticoid administration before admission. During the prestarvation period all subjects were screened to exclude cardiopulmonary, renal, hepatic, and endocrine abnormalities, as previously described (2).

During the prestarvation period of 4 or more days, subjects were fed about 2400 kcal/day, consisting of 300 g carbohydrate, 100 g protein, and 85 g fat. The method of performing intravenous glucose tolerance has been described (2).

Daily intake during starvation consisted of one multivitamin capsule (Unicap, The Upjohn Co., Kalamazoo, Mich.), 17 meq of NaCl (sugar-free tablets), 1500 ml of water, and, as tolerated, 13 meq of KCl (gelatin capsule). Blood and urine collections. Blood samples were obtained from the antecubital veins at 7:00 a.m. before the subject arose from bed as follows: 3 days prestarvation, on the day after an overnight fast (day 0), on days 3, 10, 14, 21, 28, 31, 34, and 35 before glucocorticoid administration, and every day or two during glucocorticoid administration. During the fast and after glucocorticoid administration, additional blood samples were obtained from subjects A. B., R. S., and D. D. All blood samples were analyzed for glucose, α-amino nitrogen, glycerol, acetacetate, beta-hydroxybutyrate (β-OH-butyrate), free fatty acids (FFA), immunoactive insulin (IRI), and growth hormone (HGH) by methods previously published (2, 6–8).

100 mg cortisone acetate was given intramuscularly immediately after blood was drawn and then at 12-h intervals for 6 days. Thus, the blood samples obtained on day 35 of the fast were drawn just before the glucocorticoids were given, and the blood samples obtained on days 36–41 were obtained 12 h after the previous or final dose of cortisone. An exception is C. R., in whom the blood sample obtained on day 35 represents a preinfusion specimen, and

1 Abbreviations used in this paper: FFA, free fatty acids; HGH, human growth hormone; IRI, immunoactive insulin.
The five intramuscular after and prestarvation insulin, P-OH-butyrate, toms developed. After a (13). cancence of correlation were period. the 72-h acetate and 40 days an overnight the urine measured were acetate, and aliquots were 24-h acetate, sone urea chromogens (9) nique cortisol concentration hemisuccinate. Additional intravenous infusion specimens, 72-h blood determinings for specimens were collected during those obtained during glucocorticoid administration. The urine specimens obtained from C. R. for days 35 through 37 represent those collected during the 72-h continuous intravenous hydrocortisone infusion period.

Statistical analyses. The paired t test and the coefficient of correlation were employed to determine statistical significance (13).

RESULTS

After a latent period of several hours all subjects given intramuscular cortisone acetate complained of mild persistent pain at the injection site. No other adverse symptoms developed.

The morning concentrations of circulating glucose, insulin, P-OH-butyrate, and acetoacetate throughout the prestarvation and starvation periods before, during, and after intramuscular administration of cortisone acetate to the five subjects are shown in Fig. 1. During the pre-

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Height (cm)</th>
<th>Initial Weight (kg)</th>
<th>Final Weight (kg)</th>
<th>Kt</th>
<th>Days of study *</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. C.</td>
<td>32</td>
<td>M</td>
<td>167.8</td>
<td>169.0</td>
<td>148.1</td>
<td>1.4</td>
<td>0-35 35-36</td>
</tr>
<tr>
<td>S. C.</td>
<td>33</td>
<td>F</td>
<td>163.0</td>
<td>119.0</td>
<td>101.7</td>
<td>0.7</td>
<td>0-35 35-40</td>
</tr>
<tr>
<td>A. B.</td>
<td>19</td>
<td>M</td>
<td>180.3</td>
<td>154.0</td>
<td>126.6</td>
<td>1.2</td>
<td>0-35 35-40 41-44</td>
</tr>
<tr>
<td>R. S.</td>
<td>21</td>
<td>M</td>
<td>180.0</td>
<td>160.6</td>
<td>130.8</td>
<td>1.4</td>
<td>0-35 35-40 41-49</td>
</tr>
<tr>
<td>D. D.</td>
<td>20</td>
<td>F</td>
<td>159.0</td>
<td>108.9</td>
<td>87.3</td>
<td>1.7</td>
<td>0-35 35-40 41-55</td>
</tr>
<tr>
<td>C. R.</td>
<td>16</td>
<td>F</td>
<td>167.6</td>
<td>104.1</td>
<td>85.6</td>
<td>2.1</td>
<td>0-35 35-38 38-47</td>
</tr>
</tbody>
</table>

* Intravenous glucose tolerance test (0.5 g/kg) performed before weight reduction. Values expressed as absolute per cent disappearance per minute.
† After an overnight fast, day 0, all subjects underwent total caloric starvation. After blood and urine collections were completed on the 35th morning administration of glucocorticoids was started. C. R. received hydrocortisone sodium hemisuccinate i.v. while all other subjects were given cortisol acetate i.m.

Blood drawn on days 36, 37, and 38 represents 24, 48, and 72-h specimens, respectively, obtained during the continuous intravenous infusion of 200 mg/day hydrocortisone sodium hemisuccinate. Additional blood specimens were obtained on days 35 through 38 from C. R. to determine plasma cortisol concentration by the double isotope derivative technique (9) and free plasma amino acids as previously described (10).

Urine was collected in refrigerated plastic containers for 24-h periods beginning immediately after the 7:00 a.m. blood specimens were obtained. The volumes were measured, and aliquots were frozen at −20°C until analyses of total nitrogen, urea nitrogen, uric acid, creatinine, ammonium, acetoacetate, and β-OH-butyrate were completed. Methods used for determining these urine substances have been published (2, 6). Urinary 17-hydroxycorticoids were determined as Porter-Silber chromogens (11), and urinary 17-ketosteroids were measured by the Zimmerman test (12). Day 0–day 1 designates the first 24-h urinary specimen initiated after an overnight fast. For those subjects who received cortisone acetate, the urine specimens designated as days 35 through 40 represent those obtained during glucocorticoid administration. The urine specimens obtained from C. R. for days 35 through 37 represent those collected during the 72-h continuous intravenous hydrocortisone infusion period.

Statistical analyses. The paired t test and the coefficient of correlation were employed to determine statistical significance (13).

RESULTS

After a latent period of several hours all subjects given intramuscular cortisone acetate complained of mild persistent pain at the injection site. No other adverse symptoms developed.

The morning concentrations of circulating glucose, insulin, β-OH-butyrate, and acetoacetate throughout the prestarvation and starvation periods before, during, and after intramuscular administration of cortisone acetate to the five subjects are shown in Fig. 1. During the pre-

---

**Figure 1** Individual values for circulating glucose, insulin, β-OH-butyrate, and acetoacetate before and during starvation before, during, and after intramuscular cortisone administration. Blood samples obtained on days 36–41 are those obtained 12 h after the previous dose of cortisone.

**Metabolic Effects of Glucocorticoids** 2597
TABLE II
Influence of Cortisone Administration on Circulating Hormonal and Substrate Concentrations during Prolonged Starvation*

<table>
<thead>
<tr>
<th>Experimental period day of fast</th>
<th>Precortisone</th>
<th>Cortisone acetate administration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>35</td>
<td>36–37</td>
</tr>
<tr>
<td></td>
<td>39</td>
<td>41–42</td>
</tr>
<tr>
<td>Serum insulin, µU/ml</td>
<td>8 ± 3</td>
<td>14 ± 5</td>
</tr>
<tr>
<td></td>
<td>20 ± 5†</td>
<td>27 ± 6†</td>
</tr>
<tr>
<td>Serum growth hormone, ng/ml</td>
<td>0.6 ± 0.7</td>
<td>1.3 ± 0.9</td>
</tr>
<tr>
<td></td>
<td>0.4 ± 0.2</td>
<td>0.4 ± 0.2</td>
</tr>
<tr>
<td>Blood glucose, mmol/liter</td>
<td>3.20 ± 0.09</td>
<td>3.78 ± 0.22</td>
</tr>
<tr>
<td></td>
<td>4.18 ± 0.17†</td>
<td>4.88 ± 0.23†</td>
</tr>
<tr>
<td>Plasma free fatty acids, mmol/liter</td>
<td>1.28 ± 0.16</td>
<td>1.36 ± 0.09</td>
</tr>
<tr>
<td></td>
<td>1.33 ± 0.08</td>
<td>1.24 ± 0.07</td>
</tr>
<tr>
<td>Blood glycerol, mmol/liter</td>
<td>0.108 ± 0.028</td>
<td>0.092 ± 0.12</td>
</tr>
<tr>
<td></td>
<td>0.087 ± 0.009</td>
<td>0.085 ± 0.012</td>
</tr>
<tr>
<td>Blood β-OH-butyrate, mmol/liter</td>
<td>6.12 ± 0.61</td>
<td>6.54 ± 0.55</td>
</tr>
<tr>
<td></td>
<td>5.91 ± 0.53</td>
<td>4.95 ± 0.05†</td>
</tr>
<tr>
<td>Blood acetoacetate, mmol/liter</td>
<td>1.20 ± 0.35</td>
<td>1.30 ± 0.25</td>
</tr>
<tr>
<td></td>
<td>1.48 ± 0.36</td>
<td>1.52 ± 0.38†</td>
</tr>
<tr>
<td>Serum α-amino nitrogen, mmol/liter</td>
<td>3.90 ± 0.28</td>
<td>3.63 ± 0.16</td>
</tr>
<tr>
<td></td>
<td>3.81 ± 0.11</td>
<td>3.76 ± 0.26</td>
</tr>
</tbody>
</table>

* Data presented as mean ± SEM. Data from subject P. C. is omitted since blood was obtained only on days 35 and 36.
† Probability that concentration change is statistically significantly different (P < 0.05) from precortisone period (paired t test).

cortisone starvation period each subject had the characteristic fall in blood glucose and serum insulin with the subsequent elevation of plasma FFA and blood β-OH-butyrate and acetoacetate. 6 days of cortisone acetate administration increased glucose and insulin concentrations in all subjects, including S. C., who had latent diabetes mellitus. The direct relationship of glycemia and insulinemia before, during, and after cortisone administration is displayed.

Table II presents the results of all measured circulating substrates and hormones during the precortisone and cortisone administration periods. Blood glucose and serum IRI levels increased significantly (P < 0.05) during cortisone treatment when compared with the precortisone control period. The mean peak values were detected after the last dose of cortisone acetate was administered. Although the rise in serum insulin lagged behind the glucose response in subjects R. S. and D. D., the mean peak value coincided with that of glucose. The apparent early rise in β-OH-butyrate after cortisone administration is not statistically significant (P > 0.05). However, the fall in blood β-OH-butyrate and rise in blood acetoacetate by day 41 or 42 in the four subjects who received the 6-day course of cortisone administration were significantly different (P < 0.05) from the day 35 values. The total blood ketone body (acetoacetate plus β-OH-butyrate) concentration at day 35 of 7.32 ± 0.95 mmol/liter was similar to the concentration at day(s) 41–42 of 6.47 ± 0.83 mmol/liter. The intramuscular administration of cortisone did not alter the prolonged fasting steady state concentrations of circulating FFA, glycerol, or α-amino nitrogen. Transient changes could have been missed. GHG concentrations, obtained only at 7:00 a.m. before the subjects arose remained low, less than 1.10 ng/ml, before and after glucocorticoid administration.

The effect of the slow absorption of cortisone acetate from the intramuscular depot was eliminated by administering biologically equivalent amounts of hydrocortisone intravenously to one subject, C. R. The circulating insulin and substrate responses to the constant 72-h infe-
sion of 200 mg/day of hydrocortisone sodium hemisuccinate are shown in Fig. 2. The baseline blood glucose concentration of 3.39 mmol/liter (61 mg/100 ml) progressively rose during the infusion to 5.76 mmol/liter (104 mg/100 ml), an increase of 70%. Serum insulin concentrations tended to parallel the glucose increase, rising from a baseline value of 12 µU/ml to 44 µU/ml at 48 h and 38 µU/ml at 72 h of infusion. β-OH-butyrate showed an apparent increase from a baseline concentration of 6.24 to 7.20 mmol/liter at the 24-h blood-sampling interval, then fell to 4.16 mmol/liter after 72 h of infusion. Several days after the infusion, circulating glucose, insulin, and β-OH-butyrate approached preinfusion fasting values. There was no significant response in plasma FFA or blood acetoacetate to the infused hydrocortisone. Not shown are the glycerol values, which remained constant throughout the preinfusion, infusion, and postinfusion periods. The hydrocortisone infusion elevated the baseline α-amino nitrogen from 4.00 to 4.65 mmol/liter at the 24-h interval, and then progressively depressed the levels to a minimal concentration of 3.30 mmol/liter on day 42, the fourth postinfusion day. Plasma free amino acids during fasting were measured in subject C. R. before and during the hydrocortisone infusion periods (Table III). The changes in amino acid concentrations verify the fluctuations in plasma α-amino nitrogen. Taurine, aspartic acid, threonine, serine, proline, glycine, alanine, α-amino-N-butyric acid, valine, and leucine are initially increased and subsequently depressed to baseline values. None of the amino acids declined below baseline values during the infusion period. Thus, during the 72-h infusion period both plasma α-amino nitrogen and free amino acids transiently increased and then decreased to near preinfusion concentrations. More acute effects of the steroid on amino acid concentrations were not directly examined.

The influence of 200 mg daily of cortisone acetate administered intramuscularly after 35 days of fasting on 24-h urinary total nitrogen excretion is shown in Fig. 3. There was no significant change in the total urinary nitrogen loss. However, there are shifts in the proportion of urea and ammonium. Urinary urea and ammonium nitrogen before, during, and after cortisone administration is shown in Fig. 4. The apparent increase in nitrogen excretion (urea plus ammonium) after the cessation of cortisone administration is not real (Fig. 4). It is due to the fact that total and fractional urinary nitrogenous excretory rates were measured in only three subjects (A. B., R. S., and D. D.). Two of these subjects, A. B. and R. S., had large excretory rates. The importance of continuous monitoring during the postcortisone period was not obvious when the studies were initiated. Urea excretion diminishes progressively dur-

**TABLE III**

*Influence of 72-h Hydrocortisone Infusion in One Subject (C. R.) upon Individual Plasma Free Amino Acids during Prolonged Starvation*

<table>
<thead>
<tr>
<th>Amino acid</th>
<th>Baseline</th>
<th>24-h</th>
<th>48-h</th>
<th>72-h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taurine</td>
<td>46</td>
<td>103</td>
<td>80</td>
<td>60</td>
</tr>
<tr>
<td>Aspartic acid</td>
<td>13</td>
<td>16</td>
<td>23</td>
<td>17</td>
</tr>
<tr>
<td>Threonine</td>
<td>297</td>
<td>318</td>
<td>304</td>
<td>293</td>
</tr>
<tr>
<td>Serine</td>
<td>158</td>
<td>180</td>
<td>161</td>
<td>154</td>
</tr>
<tr>
<td>Proline</td>
<td>169</td>
<td>212</td>
<td>194</td>
<td>167</td>
</tr>
<tr>
<td>Citrulline</td>
<td>16</td>
<td>13</td>
<td>15</td>
<td>18</td>
</tr>
<tr>
<td>Glycine</td>
<td>478</td>
<td>521</td>
<td>418</td>
<td>354</td>
</tr>
<tr>
<td>Alanine</td>
<td>122</td>
<td>157</td>
<td>139</td>
<td>125</td>
</tr>
<tr>
<td>α-Amino-N-butyric acid</td>
<td>33</td>
<td>51</td>
<td>47</td>
<td>45</td>
</tr>
<tr>
<td>Valine</td>
<td>136</td>
<td>194</td>
<td>187</td>
<td>156</td>
</tr>
<tr>
<td>Methionine</td>
<td>20</td>
<td>28</td>
<td>32</td>
<td>30</td>
</tr>
<tr>
<td>Isoleucine</td>
<td>59</td>
<td>80</td>
<td>77</td>
<td>72</td>
</tr>
<tr>
<td>Leucine</td>
<td>94</td>
<td>141</td>
<td>121</td>
<td>109</td>
</tr>
<tr>
<td>Tyrosine</td>
<td>49</td>
<td>55</td>
<td>59</td>
<td>59</td>
</tr>
<tr>
<td>Phenylalanine</td>
<td>50</td>
<td>68</td>
<td>71</td>
<td>66</td>
</tr>
<tr>
<td>Ornithine</td>
<td>—</td>
<td>38</td>
<td>34</td>
<td>47</td>
</tr>
<tr>
<td>Lysine</td>
<td>—</td>
<td>77</td>
<td>79</td>
<td>73</td>
</tr>
<tr>
<td>Arginine</td>
<td>—</td>
<td>78</td>
<td>100</td>
<td>79</td>
</tr>
</tbody>
</table>

* Baseline values are concentrations of individual amino acids immediately before beginning the 72-h constant infusion.

**FIGURE 3** Individual values for total nitrogen excretion in subjects before, during, and after intramuscular injection of 100 mg of cortisone acetate twice daily. The dashed horizontal lines represent the mean values in each subject for each experimental period.
During the first 4 wk of fasting, after which it remains fairly constant. Ammonium excretion reaches a maximum after about 1 wk of fasting, then plateaus, and becomes equal to or greater than urea excretion. The initial effect of intramuscular cortisone was an increase and subsequent decrease in ammonium excretion. In contrast to ammonium excretion there are reciprocal changes in urea excretion with a progressive and significant \( (P < 0.05) \) twofold increase in urea excretion noted by day 42. The oppositely directed effects of cortisone during prolonged starvation on ammonium and urea excretion canceled any net change in total urinary nitrogen. Not shown is the difference between urinary total nitrogen excretion and ammonium plus urea nitrogen excretion, which is comprised of creatinine, uric acid, amino acids, and other nitrogenous compounds. The sum of these urinary compounds also did not change significantly with cortisone administration.

Similar directional changes were obtained after administering hydrocortisone intravenously for 72 h to subject C. R. The maximal effects of hydrocortisone on urea and ammonium excretion were manifested 3-4 days after infusion. The results are presented in Fig. 5.

The fluctuation in urinary ammonium excretion before, during, and after cortisone administration are paralleled by changes in urinary \( \beta \)-OH-butyrate and acetoacetate excretion \( (r = 0.8, P < 0.01) \). There was a transient increase and a subsequent decrease in ketonuria. In one subject, C. R., intravenous hydrocortisone appeared to dissociate ketonuria temporarily from ammonium excretion. The maximal alterations in urinary excretions of urea, ammonium, \( \beta \)-OH-butyrate, and acetoacetate were present 3-4 days after cessation of cortisone or hydrocortisone administration. Data are presented in Fig. 4, 5, and 6.

Another point worthy of notation is that glucocorticoids transiently diminished renal excretion of ketone bodies (Figs. 4 and 6). This is most obvious several days after the cessation of glucocorticoids, when the blood concentrations of acetoacetate and \( \beta \)-OH-butyrate were approximately equal to the presteroid control period (Figs. 1 and 2).
The influence of intramuscular cortisone acetate 100 mg every 12 h, starting on the 35th morning and stopping on the 40th evening, on urinary excretion of 17-hydroxycorticosteroids is presented in Table IV. The low 24-h urinary excretion rates for 17-hydroxycorticosteroids during the starvation precortisone period are consistent with previously reported data (14). Delayed absorption or excretion of the exogenous administered cortisone or both is obvious. Increased excretion persisted during the postcortisone period for as long as urine was assayed for 17-hydroxy-corticosteroid content. The influences of infusion of 200 mg hydrocortisone hemisuccinate daily, starting on the 35th morning and stopping on the 38th morning, in one subject, C. R., on urinary 17-hydroxy-corticosteroid excretion rates and plasma cortisol concentrations are shown in Table V. During the

**TABLE IV**

*Daily Urinary Excretion of 17-Hydroxycorticoids*

<table>
<thead>
<tr>
<th>Experimental period</th>
<th>Precortisone 33 34</th>
<th>Cortisone administration 35 36 37 38 39 40</th>
<th>Postcortisone 41 42 43 44 45 46 47 48</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day of fast</td>
<td>12 13</td>
<td>12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48</td>
<td></td>
</tr>
<tr>
<td>P. C.</td>
<td>7 6</td>
<td>8 9 10</td>
<td>8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48</td>
</tr>
<tr>
<td>S. C.</td>
<td>1 7</td>
<td>3 0 9</td>
<td>8 9 10</td>
</tr>
<tr>
<td>A. B.</td>
<td>6 6</td>
<td>9 8 13 15 17 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73 75 77 79 81 83 85 87 89 91 93 95 97 99</td>
<td></td>
</tr>
<tr>
<td>R. S.</td>
<td>5 9</td>
<td>10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 66 68 70 72 74 76 78 80 82 84 86 88 90 92 94 96 98 100</td>
<td></td>
</tr>
<tr>
<td>D. D.</td>
<td>12 13</td>
<td>2 7 4</td>
<td>12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48</td>
</tr>
</tbody>
</table>

* The data show the changes in urinary excretion rates of 17-hydroxycorticoids before, during, and after intramuscular injection of 100 mg of cortisone acetate twice daily to five obese subjects undergoing prolonged starvation.

† Urinary collections started at 7:00 a.m. on day noted and continued until 7:00 a.m. the next day. Thus day 40 terminated on day 41.

* Metabolic Effects of Glucocorticoids* 2601
first 24 h after infusion of hydrocortisone, urinary excretion of 17-hydroxy-corticosteroids increased several-fold and remained elevated throughout the 72-h infusion period and first 24-h postinfusion period. Similarly changes in plasma cortisol levels are reported for the 72-h infusion period. The normal plasma cortisol concentration after 35 days of starvation and before hydrocortisone infusion is consistent with a previous report that circulating concentrations of cortisol are not depressed by fasting (15). From 24 to 48 h after infusion urinary 17-hydroxy-corticosteroids returned to preinfusion values.

DISCUSSION

There is a sparsity of reports describing predictable metabolic responses of humans to exogenously administered glucocorticoids. The present study gives information on the influence of large doses of glucocorticoids on circulating substrate and hormone concentrations, urinary nitrogenous products, and ketone-body excretory rates in humans. Here an attempt is made to integrate the relationships among glucocorticoids, insulin, and substrate metabolism.

It has been well established from in vitro preparations that the unopposed actions of glucocorticoids result in selected protein catabolism (16-18), inhibited protein synthesis (19-22), increased amino acid mobilization (23), and increased hepatic gluconeogenesis appropriately accompanied by increased amino acid-metabolizing enzymes (24-26). Data obtained from intact animals and humans are not so definitive. If glucocorticoids are able to induce net protein catabolism with amino acid mobilization and hypergluconeogenesis, an increased urinary excretion of nitrogen would be expected. Data pertaining to nitrogen balance in humans subjected to excessive amounts of glucocorticoids have failed to support this pattern.

In 1943 Albright reported that the “nitrogen minimum excretion (i.e., nitrogen excretion on a high-caloric, low-protein intake)” in two patients with Cushing’s syndrome was no more than that observed in normal man (27). Parson, Crispell, and Ebbert, in their studies using [14C]glycine in ACTH-treated normal man, found only a minimal and transient negative nitrogen balance in two or three experiments (28). However, there was a striking alteration in the metabolism of glycine, in that a large fraction of this amino acid was converted into urea and excreted in the urine. Conversely, a smaller fraction was available for synthetic processes. Eliel and Heaney observed a patient, maintained on an isocaloric, zero-amino acid intake, whose urinary nitrogen excretion stabilized at about 2.0 g/day. With subsequent administration of 200-600 mg of cortisone acetate daily there was a transient increase in nitrogen excretion of only 0.1 g/day (29). We did not observe a significant increase in total urinary nitrogen excretion after giving glucocorticoids. There was a decrease in ammonium excretion with a concomitant increase in urea excretion, suggesting a partial shift from renal to hepatic gluconeogenesis (2). These oppositely directed effects on urea and ammonium excretion negate a net change in gluconeogenesis from amino acids. Furthermore, since urinary nitrogen excretion is a reliable index of protein breakdown in subjects fasting for prolonged periods (30), the failure to demonstrate an increase in total urinary nitrogen excretion after the administration of glucocorticoids to fasting man suggests that the catabolic effects of these hormones during a state of fasting were absent or minimal.

After administering glucocorticoids, elevated or depressed concentrations of circulating amino acids or both have been reported in both animal and human experiments (31-35). Previous studies suggested that these differences appear to be time-related (36). The intravenous infusion of hydrocortisone resulted in a transient elevation and subsequent decline of plasma α-amino nitrogen as well as in individual amino acids. The initial elevation induced by glucocorticoids is con-
sistent with an increase in amino acid mobilization from the peripheral tissues (37). A feasible explanation for the subsequent depression is the decreased release of amino acids from muscle (the body's principal protein store) coincident with the secondary hyperinsulinemia (38) that developed after glucocorticoid administration. It is unlikely that the decline was due to an increased net removal of amino acids by the liver and kidney since urea plus ammonium nitrogen excreted did not increase. Furthermore, glucocorticoid-induced hyperaminoaciduria as a means of elimination of significant quantities of nitrogen (35, 39), is improbable since there was no substantial change in renal excretion of "unmeasured" urinary nitrogen. It appears that the potential catabolic action of excessive glucocorticoids was offset by the anabolic effect of insulin, and a new state of homeostasis was established. A possibility is that glucocorticoids may have enhanced synthesis of specific proteins, at the expense of other catabolized proteins. Such action(s) could shift the protein mass of different organs without affecting total body nitrogen balance. The data from this study do not allow assessment of this possibility.

The hyperglycemia that develops after the administration of glucocorticoids may reflect altered rates of gluconeogenesis, peripheral glucose utilization, any combination of the two, or unaltered rates with merely a changed concentration in substrate. Long, Katzin, and Fry reported in 1940 that treating normal rats with cortical extract increased the amount of glucose present in the blood and tissue fluids. Concurrently, there was no change in oxygen consumption, indicating that total calories consumed remain constant. There was a decrease in the respiratory quotient showing a shift in the source of energy from carbohydrate to fat (40). Thorn, Koepf, Lewis, and Olsen reported that in patients with Addison's disease, glucocorticoids increased the fasted blood glucose concentration, decreased the respiratory quotient, and normalized the basal metabolic requirement (41). Subsequent investigators showed that physiological concentrations of glucocorticoids decreased glucose uptake in animal adipose tissue, muscle, lymphoid tissue, and skin (25, 42, 43). Thus, the hyperglycemia induced by glucocorticoids is due, at least in part, to diminished peripheral uptake. However, the influence of glucocorticoids on carbohydrate consumption appears to be small and transient.

In this study, the urinary nitrogen excretion did not increase after glucocorticoid administration. This suggests that the fasting hyperglycemia was due to a resetting of the glucose-insulin relationship rather than to increased gluconeogenesis. After a fast of 3 or more days, peripheral tissues of man, mainly muscle and adipose tissue, derive about 10% of their substrate requirements from glucose oxidation (44). This amounts to approximately 10 g of glucose oxidized/day by peripheral tissues. We can assume that these obese starved subjects (see Table I) have a glucose space of about 15% of their body weight (45) or 18 liters, and that blood glucose equals the glucose concentration throughout the free glucose pool. The increase in blood glucose from day 35, prednisone, to days 41-42, cortisone acetate administration, of 1.68 mmol/liter (see Table II) would equal an accumulation of only 5 g of glucose in its pool over the 6-7 day observation period. If the production of glucose remained constant, diminishing glucose oxidation by less than 1 g/day could account for the observed fasting hyperglycemia after glucocorticoid administration. Calculations of similar magnitude can be made for subject of C. R., who received intravenous hydrocortisone sodium hemisuccinate.

Glucocorticoids not only reduce glucose uptake by adipose tissue and play a permissive role in normalizing and/or potentiating the catecholamines and HGH-induced release of FFA (46-49), but also possess a direct effect on mobilizing FFA from adipose tissue (50). However, their lipolytic effect can be overcome by insulin (50). Therefore, it is not surprising that the adipokinetin actions of glucocorticoids in animals or humans have been variously reported to progressively increase (51), transiently decrease (52), or to leave unchanged (53) the release of FFA from adipose tissue. Perhaps these differences are related to the evoked insulin responses. In this study there were no significant changes in the circulating concentrations of FFA or glycerol after administration of glucocorticoids. The potential adipokinetin effects of glucocorticoids could have been masked by the resulting hyperinsulinemia with its antilipolytic action. It is not disturbing to note that in these patients, the blood glucose levels rose while plasma FFA remained unchanged, since more insulin is required to promote translocation of glucose than is needed to block lipolysis (54, 55).

The ketogenic interplay between insulin and glucocorticoids deserve special consideration. The administration of glucocorticoids to animals or humans with coexisting diabetes mellitus and adrenal insufficiency showed intensification of ketonemia and ketonuria (56-58). Kinsell et al. showed that the administration of ACTH accelerated the development and augmented the degree of ketoacidosis in a severely diabetic patient deprived of food and insulin (59). Additional insulin corrected the catabolic state induced by glucocorticoids. On the other hand, administering ACTH or cortisone to individuals without pre-existing endocrinopathies resulted in suppression of fasting-induced hyperketonemia and ketonuria (59). Similarly, Scott and Engel showed that in normal rats cortisone and hydrocortisone sup-
pressed both fasting and cold stress ketosis (60). In essence, previous studies showed that glucocorticoids suppressed the development of fasting hyperketonemia and ketonuria if the pancreas was intact. In our study fasting hyperketonemia and ketonuria were well established before glucocorticoid administration. Intramuscular cortisone did not significantly change the total concentration of circulating ketone bodies, although a slight reduction in the β-OH-butyrate/acetocetate ratio was observed. Since β-OH-butyrate is the major ketone body present in the blood after prolonged starvation, it is possible that continuous administration may have significantly depressed circulating concentrations of ketone bodies. Administration of intravenous hydrocortisone in one subject suppressed blood β-OH-butyrate concentrations without significantly increasing blood acetocetate concentrations and, therefore, depressed total ketonemia. This occurred while plasma FFA concentrations remained unchanged.

Increasing evidence indicates that hepatic production of ketone bodies is influenced by hormones as well as the supply of ketogenic precursors (61). The hyperinsulinemia we observed after glucocorticoid administration may have suppressed hepatic ketone body production without modifying the delivery of FFA to the liver (61).

ACKNOWLEDGMENTS

The authors wish to express their appreciation to Daidra Rumba, Adacie Allen, Velta Ramolins, Wilma Lauris, and Anna Karras for their expert technical assistance, to the nurses and staff of the Clinical Center at the Peter Bent Brigham Hospital, and to Rachelle Masloff for her secretarial assistance. Amino acid analyses were kindly performed by Dr. T. T. Aoki.

This work was supported in part by U. S. Public Health Service NIH Grants AM-05077, AM-15191 and Grants FR-31 and RR 349, General Clinical Research Centers Branch, National Institutes of Health.

REFERENCES

29. Flahart, W. P., and R. F. H
textsuperscript{1}tomized-diabetic rats. Endocrinology. 80: 561.
textsuperscript{1}lectomized-diabetic rats. Endocrinology. 80: 561.
52. Drelling, D. A., E. L. Bierman, A. F. Debons, P. E. Els

Metabolic Effects of Glucocorticoids 2605